Study of how tranexamic acid works in ovarian cancer patients
Pharmacokinetic Study and Clinical Efficacy Observation of Different Routes of Tranexamic Acid Infusion in Advanced Ovarian Cancer Cell Reduction Surgery
This study is testing how well tranexamic acid works in reducing blood loss during surgery for women with advanced ovarian cancer by comparing two different ways of giving the medication.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 20 Years to 64 Years |
| Sex | Female |
| Sponsor | Zhejiang Cancer Hospital Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06728670 on ClinicalTrials.gov |
What this trial studies
This study investigates the pharmacokinetics of tranexamic acid (TXA) in adult women with advanced ovarian cancer undergoing cytoreductive surgery. It aims to compare the effects of TXA administered through intravenous and intramuscular routes on intraoperative blood loss, transfusion volume, and postoperative complications. A total of 30 patients will be recruited, and their pharmacokinetic parameters will be recorded to understand how different administration methods impact treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates are adult women aged 20-64 with advanced ovarian cancer (stage III-IV) who are scheduled for cytoreductive surgery.
Not a fit: Patients with renal or liver dysfunction, serious mental illness, bleeding disorders, or those allergic to TXA may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could optimize the use of tranexamic acid to reduce blood loss and improve recovery in ovarian cancer patients undergoing surgery.
How similar studies have performed: While there is limited data on the pharmacokinetics of TXA in ovarian cancer patients, previous studies have shown its effectiveness in reducing blood loss in surgical settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult women aged 20-64 diagnosed with advanced ovarian cancer undergoing cytoreductive surgery 2. The cancer stage is III-IV 3. ASA classification II-III 4. Surgical duration\>2 hours Exclusion Criteria: 1. Renal dysfunction (serum creatinine\>200 mmol/L) or liver dysfunction (Child Turcote classification\>6) 2. Has a history of serious mental illness or disorders, epilepsy, visual impairment 3. Previous or current bleeding disorders, coagulation dysfunction, or thromboembolic events 4. Lower limb venous thrombosis 5. Anticoagulants or antifibrinolytic drugs used before surgery within the past month 6. Allergic to TXA
Where this trial is running
Hangzhou, Zhejiang
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Yejing Zhu, PHD
- Email: zhuyejing1983@126.com
- Phone: 86+18758096745
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.